Scott Donlea
Analyste en capital-investissement chez Denargo Capital LLC
Profil
Mr. Scott Donlea is an Associate at Denargo Capital LLC.
He joined Denargo Capital in August 2008.
Previously, he was Senior Vice President, Networks and Product Development of RCC, leading a staff of 140 technicians, managers, directors and engineers and overseeing a $140 million annual operating and capital budget.
Mr. Donlea was a key member of the senior management team leading the growth of Rural Cellular (NASDAQ RCCC) from start-up to $800 million in revenue.
Mr. Donlea's leadership included the development and implementation of strategies for sales and marketing, engineering management, product development, network operations, and IT.
As the first employee and employee officer (VP, Sales and Marketing), he was lead member of the IPO team that took RCC public in 1996.
In 1999, he was the Rural Cellular Association Man of the Year.
Postes actifs de Scott Donlea
| Sociétés | Poste | Début |
|---|---|---|
Denargo Capital LLC
 Denargo Capital LLC Investment ManagersFinance Denargo Capital LLC (Denargo Capital) is a private equity firm founded in 2003 by Tom D. Heule, Pål Berg and Paul A. Lyons. The firm is headquartered in Greenwood Village, Colorado. | Analyste en capital-investissement | 01/08/2008 |
Anciens postes connus de Scott Donlea
| Sociétés | Poste | Fin |
|---|---|---|
RCC
 RCC Miscellaneous Commercial ServicesCommercial Services RCC is a Norwegian company that focuses on kidney cancer, which is one of the top 10 most commonly diagnosed forms of cancer among both men and women in the United States. Clear cell RCC is the most common type of kidney cancer in adults, while NCCRCC represents about 20-25%% of RCC cases, with fewer treatment options available and poorer outcomes compared with clear cell RCC. The company highlights the importance of early detection, as the five-year survival rate is high for patients with early-stage RCC. However, for patients with advanced or late-stage metastatic RCC, the five-year survival rate is only 14%%. RCC was acquired by AGR Ability Group on January 18, 2005 for $22.35 million. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
RCC
RCC Miscellaneous Commercial ServicesCommercial Services RCC is a Norwegian company that focuses on kidney cancer, which is one of the top 10 most commonly diagnosed forms of cancer among both men and women in the United States. Clear cell RCC is the most common type of kidney cancer in adults, while NCCRCC represents about 20-25%% of RCC cases, with fewer treatment options available and poorer outcomes compared with clear cell RCC. The company highlights the importance of early detection, as the five-year survival rate is high for patients with early-stage RCC. However, for patients with advanced or late-stage metastatic RCC, the five-year survival rate is only 14%%. RCC was acquired by AGR Ability Group on January 18, 2005 for $22.35 million. | Commercial Services |
Denargo Capital LLC
Denargo Capital LLC Investment ManagersFinance Denargo Capital LLC (Denargo Capital) is a private equity firm founded in 2003 by Tom D. Heule, Pål Berg and Paul A. Lyons. The firm is headquartered in Greenwood Village, Colorado. | Finance |
